Gilead Reports real-world evidence Data for Trastuzumab in Coronary artery disease

Gilead today announced real-world evidence results for trastuzumab in patients with coronary artery disease. The study demonstrated that trastuzumab achieves complete response compared to standard of care or placebo. These results provide important insights into the treatment of coronary artery disease and support the continued development of trastuzumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.